Facial-muscle weakness, speech disorders and dysphagia are common in patients with classic infantile Pompe disease treated with enzyme therapy
Tóm tắt
Classic infantile Pompe disease is an inherited generalized glycogen storage disorder caused by deficiency of lysosomal acid α-glucosidase. If left untreated, patients die before one year of age. Although enzyme-replacement therapy (ERT) has significantly prolonged lifespan, it has also revealed new aspects of the disease. For up to 11 years, we investigated the frequency and consequences of facial-muscle weakness, speech disorders and dysphagia in long-term survivors. Sequential photographs were used to determine the timing and severity of facial-muscle weakness. Using standardized articulation tests and fibreoptic endoscopic evaluation of swallowing, we investigated speech and swallowing function in a subset of patients. This study included 11 patients with classic infantile Pompe disease. Median age at the start of ERT was 2.4 months (range 0.1-8.3 months), and median age at the end of the study was 4.3 years (range 7.7 months −12.2 years). All patients developed facial-muscle weakness before the age of 15 months. Speech was studied in four patients. Articulation was disordered, with hypernasal resonance and reduced speech intelligibility in all four. Swallowing function was studied in six patients, the most important findings being ineffective swallowing with residues of food (5/6), penetration or aspiration (3/6), and reduced pharyngeal and/or laryngeal sensibility (2/6). We conclude that facial-muscle weakness, speech disorders and dysphagia are common in long-term survivors receiving ERT for classic infantile Pompe disease. To improve speech and reduce the risk for aspiration, early treatment by a speech therapist and regular swallowing assessments are recommended.
Tài liệu tham khảo
Amalfitano A, Bengur AR, Morse RP et al. (2001) Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med 3:132–138
Begley DJ, Pontikis CC, Scarpa M (2008) Lysosomal storage diseases and the blood-brain barrier. Curr Pharm Des 14:1566–1580
Bijvoet AG, Van Hirtum H, Kroos MA et al. (1999) Human acid alpha-glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II. Hum Mol Genet 8:2145–2153
Chakrapani A, Vellodi A, Robinson P, Jones S, Wraith JE (2010) Treatment of infantile Pompe disease with alglucosidase alpha: the UK experience. J Inherit Metab Dis 33:747–750
Darley FL, Aronson AE, Brown JR (1969a) Clusters of deviant speech dimensions in the dysarthrias. J Speech Hear Res 12:462–496
Darley FL, Aronson AE, Brown JR (1969b) Differential diagnostic patterns of dysarthria. J Speech Hear Res 12:246–269
Drost MR, Schaart G, van Dijk P et al. (2008) Both type 1 and type 2a muscle fibers can respond to enzyme therapy in Pompe disease. Muscle Nerve 37:251–255
Dubowitz V (1978) Muscle Disorders in Childhood. Sauders, London and Philadelphia
Gambetti P, DiMauro S, Baker L (1971) Nervous system in Pompe's disease. Ultrastructure and biochemistry. J Neuropathol Exp Neurol 30:412–430
Hirschhorn R, Reuser AJJ (2001) Glycogen storage disease type II: acid alpha-glucosidase (acid maltase) deficiency. In: Scriver CR, Beaudet AL, Valle D, Sly WS (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 3389–3420
Hoh JF (2005) Laryngeal muscle fibre types. Acta Physiol Scand 183:133–149
Kent RD (2004) The uniqueness of speech among motor systems. Clin Linguist Phon 18:495–505
Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D, Infantile-Onset Pompe Disease Natural History Study Group (2006a) A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 148:671–676
Kishnani PS, Nicolino M, Voit T et al. (2006b) Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr 149:89–97
Kishnani PS, Corzo D, Nicolino M et al. (2007) Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 68:99–109
Kishnani PS, Corzo D, Leslie ND et al. (2009) Early treatment with alglucosidase alfa prolongs long term survival of infants with Pompe disease. Pediatr Res 66:329–335
Klinge L, Straub V, Neudorf U et al. (2005a) Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial. Neuromuscul Disord 15:24–31
Klinge L, Straub V, Neudorf U, Voit T (2005b) Enzyme replacement therapy in classical infantile pompe disease: results of a ten-month follow-up study. Neuropediatrics 36:6–11
Kobayashi H, Shimada Y, Ikegami M et al. (2010) Prognostic factors for the late onset Pompe disease with enzyme replacement therapy: from our experience of 4 cases including an autopsy case. Mol Genet Metab 100:14–19
Langmore SE (2001) Endoscopic Evaluation and Treatment of Swallowing Disorders. Thieme Medical Publishers, New York
Langmore SE, Schatz K, Olsen N (1988) Fiberoptic endoscopic examination of swallowing safety: a new procedure. Dysphagia 2:216–219
Mancall EL, Aponte GE, Berry RG (1965) Pompe's Disease (Diffuse Glycogenosis) with Neuronal Storage. J Neuropathol Exp Neurol 24:85–96
Martin JJ, de Barsy T, van Hoof F, Palladini G (1973) Pompe's disease: an inborn lysosomal disorder with storage of glycogen. A study of brain and striated muscle. Acta Neuropathol 23:229–244
Muller CW, Jones HN, O'Grady G, Suarez AH, Heller JH, Kishnani PS (2009) Language and speech function in children with infantile Pompe disease. J Pediatr Neurol 7:147–156
Nicolino M, Byrne B, Wraith JE et al. (2009) Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet Med 11:210–219
Pompe JC (1932) Over Idiopathische Hypertrofie van het Hart. Ned Tijdschr Geneeskd 76:304–311
Raben N, Fukuda T, Gilbert AL et al. (2005) Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers. Mol Ther 11:48–56
Rudnick EF, Sie KC (2008) Velopharyngeal insufficiency: current concepts in diagnosis and management. Curr Opin Otolaryngol Head Neck Surg 16:530–535
Sakurai I, Tosaka A, Mori Y, Imura S, Aoki K (1974) Glycogenosis type II (Pompe). The fourth autopsy case in Japan. Acta Pathol Jpn 24:829–846
Sciote JJ, Horton MJ, Rowlerson AM, Link J (2003) Specialized cranial muscles: how different are they from limb and abdominal muscles? Cells Tissues Organs 174:73–86
Slingerland NW, Polling JR, van Gelder CM, van der Ploeg AT, Bleyen I (2011) Ptosis, extraocular motility disorder, and myopia as features of pompe disease. Orbit 30:111–113
Van Capelle CI, Goedegebure A, Homans NC, Hoeve HL, Reuser AJ, van der Ploeg AT (2010) Hearing loss in Pompe disease revisited: results from a study of 24 children. J Inherit Metab Dis 33:597–602
Van den Hout H, Reuser AJ, Vulto AG, Loonen MC, Cromme-Dijkhuis A, Van der Ploeg AT (2000) Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet 356:397–398
Van den Hout HM, Hop W, van Diggelen OP et al. (2003) The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics 112:332–340
Van den Hout JM, Kamphoven JH, Winkel LP et al. (2004) Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 113:e448–e457
Van der Ploeg AT, Reuser AJ (2008) Pompe's disease. Lancet 372:1342–1353